A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths vs placebo.

Saved in:
Bibliographic Details
Published in:European Respiratory Journal 2021-10, Vol.58 (4), p.2100673
Main Authors: Singh, Dave, Bogus, Maxim, Moskalenko, Valentyn, Lord, Robert, Moran, Edmund J, Crater, Glenn D, Bourdet, David L, Pfeifer, Nathan D, Woo, Jacky, Kaufman, Elad, Lombardi, David A, Weng, Emily Y, Nguyen, Tuan, Woodcock, Ashley, Haumann, Brett, Saggar, Rajeev
Format: Article
Language:English
Subjects:
Administration, Inhalation
Agora
COVID-19
Humans
Janus Kinase Inhibitors
Janus Kinases
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths vs placebo.
ISSN:0903-1936
1399-3003
DOI:10.1183/13993003.00673-2021